Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

著者: Scott Antonia, José A. López-Martín, Johanna C. Bendell, Patrick A. Ott, Matthew H. Taylor, Joseph P. Eder, Dirk Jäger, M. Catherine Pietanza, Dung T. Le, Filippo de Braud, Michael A. Morse, Paolo A. Ascierto, Leora Horn, Asim Amin, Rathi N. Pillai, Jeffry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee Sharma, Christopher Harbison, Chen-Sheng Lin, Olaf Christensen, Emiliano Calvo - The Lancet 2016 被引用: 1,254